Targeted inhibition of kinases in cancer therapy

Mount Sinai Journal of Medicine

Volumn 77, Issue 6, 2010, Pages 573-586

  Baker, Stacey J ^a   Reddy, E Premkumar ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

kinase inhibitor; monoclonal antibody; small molecule inhibitors; targeted therapy

Indexed keywords

BCR ABL PROTEIN; CETUXIMAB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DANUSERTIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; NILOTINIB; PANITUMUMAB; PHOSPHOTRANSFERASE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; REVIEW; SEQUENCE ANALYSIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THIAZOLES;

EID: 78649659492     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20220     Document Type: Review

References (140)

1. Nowell PC, Hungerford DA., A minute chromosome in human granulocytic leukemia. Science 1960; 132: 1497.
2. ′ translocation. Nature 1985; 315: 758-761.
3. Shah NP, Sawyers CL., Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389-7395.
4. Hehlmann R., Current CML therapy: progress and dilemma. Leukemia 2003; 17: 1010-1012.
5. Druker BJ, Tamura S, Buchdunger E, et al., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
6. Apperley JF., Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8: 1116-1128.
7. Deininger M, Buchdunger E, Druker BJ., The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640-2653.
8. Mashkani B, Griffith R, Ashman LK,. Colony-stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem 2010; 18: 1789-1797.
9. Hantschel O, Rix U, Schmidt U, et al., The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007; 104: 13283-13288.
10. Deininger MW, Goldman JM, Lydon N, et al., The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-3698.
11. Le Coutre P, Tassi E, Varella-Garcia M, et al., Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000; 95: 1758-1766.
12. Mahon FX, Deininger MW, Schultheis B, et al., Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
13. Weisberg E, Griffin JD., Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498-3505.
14. Gorre ME, Mohamed M, Ellwood K, et al., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
15. Hochhaus A, Kreil S, Corbin AS, et al., Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
16. Donato NJ, Wu JY, Stapley J, et al., BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698.
17. Donato NJ, Wu JY, Stapley J, et al., Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672-677.
18. Wu J, Meng F, Kong LY, et al., Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926-939.
19. + progenitors via JAK-2/STAT-5 pathway activation. Blood 2007; 109: 2147-2155.
20. Burchert A, Wang Y, Cai D, et al., Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005; 19: 1774-1782.
21. Miething C, Grundler R, Mugler C, et al., Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci U S A 2007; 104: 4594-4599.
22. + cells. Blood 2004; 103: 3167-3174.
23. Wendel HG, de Stanchina E, Cepero E, et al., Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A 2006; 103: 7444-7449.
24. Burchert A., Roots of imatinib resistance: a question of self-renewal? Drug Resist Updat 2007; 10: 152-161.
25. Schindler T, Bornmann W, Pellicena P, et al., Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
26. Jiang X, Saw KM, Eaves A, et al., Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680-693.
27. Jiang X, Zhao Y, Smith C, et al., Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-935.
28. Canitrot Y, Falinski R, Louat T, et al., p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood 2003; 102: 2632-2637.
29. Sliwinski T, Czechowska A, Szemraj J, et al., STI571 reduces NER activity in BCR/ABL-expressing cells. Mutat Res 2008; 654: 162-167.
30. Stoklosa T, Poplawski T, Koptyra M, et al., BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68: 2576-2580.
31. Sawyers CL., Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2004; 17: 2998-3010.
32. Lombardo LJ, Lee FY, Chen P, et al., Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
33. Shah NP, Tran C, Lee FY, et al., Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
34. Le Coutre P, Schwarz M, Kim TD., New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. Clin Cancer Res 2010; 16: 1771-1780.
35. Nam S, Kim D, Cheng JQ, et al., Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189.
36. Schittenhelm MM, Shiraga S, Schroeder A, et al., Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-481.
37. Tokarski JS, Newitt JA, Chang CY, et al., The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790-5797.
38. O'Hare T, Walters DK, Stoffregen EP, et al., In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 66: 4500-4505.
39. Ramirez P, DiPersio JF., Therapy options in imatinib failures. Oncologist 2008; 13: 424-434.
40. Soverini S, Colarossi S, Gnani A, et al., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Hematologica 2007; 92: 401-404.
41. Khorashad JS, Milojkovic D, Mehta P, et al., In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008; 111: 2378-2381.
42. Burgess MR, Skaggs BJ, Shah NP, et al., Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005; 102: 3395-3400.
43. Soverini S, Martinelli G, Colarossi S, et al., Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 2006; 24: e51-e52.
44. Shah NP, Skaggs BJ, Branford S, et al., Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562-2569.
45. Lee F, Fandi A, Voi M., Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 2008; 40: 334-343.
46. Weisberg E, Manley PW, Breitenstein W, et al., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl [published correction appears in Cancer Cell 2005; 7: 399]. Cancer Cell 2005; 7: 129-141.
47. Stover EH, Chen J, Lee BH, et al., The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106: 3206-3213.
48. Manley PW, Cowan-Jacob SW, Fendrich G, et al., Molecular interactions between the highly selective pan-Bcr-Abl inhibitor, AMN107, and the tyrosine kinase domain of Abl. Blood 2005; 106:abstract 3365.
49. Golemovic M, Verstovsek S, Giles F, et al., AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941-4947.
50. Kantarjian H, Giles F, Wunderle L, et al., Nilot- inib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
51. Deininger MW., Nilotinib. Clin Cancer Res 2008; 14: 4027-4031.
52. O'Hare T, Eide CA, Tyner JW, et al., SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A 2008; 105: 5507-5512.
53. Quintás-Cardama A, Kantarjian H, Cortes J., Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834-848.
54. Quintás-Cardama A, Cortes J., Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res 2008; 14: 4392-4399.
55. Zhang J, Adrián FJ, Jahnke W, et al., Targeting Bcr-Abl by combining allosterix with ATP-binding-site inhibitors. Nature 2010; 463: 501-506.
56. Anderson SM, Hayward WS, Neel BG, et al., Avian erythroblastosis virus produces two mRNAs. J Virol 1980; 36: 676-683.
57. Vennström B, Bishop JM., Isolation and characterization of chicken DNA homologous to the two putative oncogenes of avian erythroblastosis virus. Cell 1982; 28: 135-143.
58. Yamamoto T, Hihara H, Nishida T, et al., A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. Cell 1983; 34: 225-232.
59. Velu TJ, Beguinot L, Vass WC, et al., Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 1987; 238: 1408-1410.
60. Hudziak RM, Schlessinger J, Ullrich A., Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987; 84: 7159-7163.
61. Pao W, Miller VA, Kris MG., 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Sem Cancer Biol 2004; 14: 33-40.
62. Ward WH, Cook PN, Slater AM, et al., Epidermal growth factor receptor tyrosine kinase: investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 1994; 48: 659-666.
63. Sirotnak FM., Studies with ZD1839 in preclinical models. Semin Oncol 2003; 30: 12-20.
64. Wakeling AE, Guy SP, Woodburn JR, et al., ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-5754.
65. Magne N, Fischel JL, Dubreuil A, et al., Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002; 86: 1518-1523.
66. Di Gennaro E, Barbarino M, Bruzzese F, et al., Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 2003; 195: 139-150.
67. Ciardiello F, Caputo R, Bianco R, et al., Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 2958-2970.
68. Hirata A, Ogawa S, Kometani T, et al., ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-2560.
69. Ono M, Kuwano M., Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeted drugs. Clin Cancer Res 2006; 12: 7242-7251.
70. Fukui T, Mitsudomi T., Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg 2008; 56: 97-103. (Pubitemid 351419126)
71. Lynch TJ, Bell DW, Sordella R, et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 3129-3139.
72. Paez JG, Jänne PA, Lee JC, et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
73. Pao W, Miller V, Zakowski M, et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-13311.
74. Irmer D, Funk JO, Blaukat A., EGFR kinase domain mutations: functional impact and relevance for lung cancer therapy. Oncogene 2007; 26: 5693-5701.
75. Riely GJ, Pao W, Pham D, et al., Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12: 839-844.
76. Jänne PA, Johnson BE., Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006; 12 (14 part 2): 4416S-4420S.
77. Cappuzzo F, Magrini E, Ceresoli GL, et al., Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96: 1133-1141. (Pubitemid 39207049)
78. Ono M, Hirata A, Kometani T, et al., Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465-472.
79. Han SW, Hwang PG, Chung DH, et al., Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113: 109-115.
80. Pollack VA, Savage DM, Baker DA, et al., Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-748.
81. Lal A, Glazer CA, Martinson HM, et al., Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002; 62: 3335-3339.
82. Bareschino MA, Schettino C, Troiani T, et al., 2007. Erlotinib in cancer treatment. Ann Oncol 2007; 18 (suppl): vi35-vi41.
83. Gridelli C, Bareschino MA, Schettino C, et al., Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 2007; 12: 840-849.
84. Kobayashi S, Boggon TJ, Dayaram T, et al., EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792. (Pubitemid 40271173)
85. Pao W, Miller VA, Politi KA, et al., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med 2005; 3: 225-235.
86. Bell DW, Gore I, Okimoto RA, et al., Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005; 37: 1315-1316.
87. Godin-Heymann N, Bryant I, Rivera MN, et al., Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007; 67: 7319-7326.
88. Yun CH, Mengwasser KE, Toms AV, et al., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070-2075.
89. Kosaka T, Yatabe Y, Endoh H, et al., Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12: 5764-5769.
90. Balak MN, Gong Y, Riely GJ, et al., Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12: 6494-6501.
91. Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: 57-61.
92. Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
93. Bean J, Brennan C, Shih JY, et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104: 20932-20937.
94. Engelman JA, Mukohara T, Zejnullahu K, et al., Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006; 116: 2695-2706.
95. Morgillo F, Woo JK, Kim ES, et al., Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66: 10100-10111.
96. Guix M, Faber AC, Wang SE, et al., Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619.
97. Mueller KL, Hunter LA, Ethier SP, et al., Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008; 68: 3314-3322.
98. Rabindran SK, Discafani CM, Rosfjord EC, et al., Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004; 64: 3958-3965.
99. Kwak EL, Sordella R, Bell DW, et al., Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005; 102: 7665-7670.
100. Li D, Shimamura T, Ji H, et al., Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12: 81-93.
101. Godin-Heymann N, Ulkus L, Brannigan BW, et al., The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008; 7: 874-879.
102. Schechter AL, Stern DF, Vaidyanathan L, et al., The neu oncogene: an erb-B related gene encoding a 185,000-Mr tumor antigen. Nature 1984; 312: 513-516.
103. King CR, Kraus MH, Aaronson SA., Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974-976.
104. Di Fiore PP, Pierce JH, Fleming TP, et al., Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987; 51: 1063-1070.
105. Bouchard L, Lamarre L, Tremblay PJ, et al., Stochastic appearance of mammary tumors in transgenic mice carrying the mmtv/c-meu oncogene. Cell 1989; 57: 931-936.
106. Slamon DJ, Clark GM, Wong SG, et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
107. Berger MS, Locher GW, Saurer S, et al., Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238-1243.
108. Slamon DJ, Godolphin W, Jones LA, et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
109. Kruser TJ, Wheeler DL., Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010; 316: 1083-1100.
110. Sliwkowski MX, Lofgren JA, Lewis GD, et al., Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26 (4 suppl 12): 60-70.
111. Harries M, Smith I., The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002; 9: 75-85.
112. Carter P, Presta L, Gorman CM, et al., Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89: 4285-4289.
113. Nahta R, Esteva EJ., HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003; 9: 5078-5084.
114. Junttila TT, Akita RW, Parsons K, et al., Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15: 429-440.
115. Carter CA, Kelly RJ, Giaccone G., Small-molecule inhibitors of the human epidermal receptor family. Expert Opin Invest Drugs 2009; 18: 1829-1842.
116. Yakes FM, Chinratanalab W, Ritter CA, et al., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62: 4132-4141.
117. Ye D, Mendelsohn J, Fan Z., Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18: 731-738.
118. Lane HA, Beuvink I, Motoyama AB, et al., ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000; 20: 3210-3223.
119. Le XF, McWatters A, Wiener J, et al., Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 2000; 6: 260-270.
120. Neve RM, Sutterlüty H, Pullen N, et al., Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000; 19: 1647-1656.
121. KIP1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer 2004; 112: 492-501.
122. Petit AM, Rak J, Hung MC, et al., Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-1530.
123. Izumi Y, Xu L, di Tomaso E, et al., Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-280.
124. Molina MA, Codony-Servat J, Albanell J, et al., Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749.
125. Cobleigh MA, Vogel CL, Tripathy D, et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
126. Vogel CL, Cobleigh MA, Tripathy D, et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
127. Roy V, Perez EA., Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 2009; 14: 1061-1069.
128. Lu Y, Zi X, Zhao Y, et al., Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-1857.
129. kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64: 3981-3986. (Pubitemid 38697313)
130. Lu Y, Zi X, Pollak M., Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108: 334-341.
131. Nahta R, Yuan LX, Zhang B, et al., Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128.
132. Leslie NR, Downes CP., PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004; 382 (part 1): 1-11.
133. Nagata Y, Lan KH, Zhou X, et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
134. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH., Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173: 4699-4707.
135. Lurje G, Lenz HJ., EGFR signaling and drug discovery. Oncology 2009; 77: 400-410.
136. Perez-Torres M, Guix M, Gonzalez A, et al., Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem 2006; 281: 40183-40192.
137. Doody JF, Wang Y, Patel SN, et al., Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 2007; 6: 2642-2651.
138. Steiner P, Joynes C, Bassi R., Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin Cancer Res 2007; 13: 1540-1551.
139. Wu M, Rivkin A, Pham T., Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 2008; 30: 14-30.
140. Amado RG, Wolf M, Peeters M., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.